Menu
Menu
Menu
Chairs: Vincent Leroy, Fabrice Carrat
The new treatment guidelines for CHB and CHD: are we moving towards functional cure?
Markus Cornberg, Hanover
Impact of HBV DNA integration on functional cure
Patrick Kennedy, London
Roundtable discussion
Chairs: David Durantel, Hélène Strick-Marchand
Integrative analysis of HBV and immune cells in the liver compartment during antiviral therapy
Michael Biermer, Janssen Belgium
Novel insight in the regulation of cccDNA transcription
Barbara Testoni, Lyon
Mechanism of exhaustion of B and T cells and path for functional revovery
Robert Thimme, Freiburg
Roundtable discussion
Chairs: Christine Neuveut, Patrick Soussan
Young investigators,
Role of H2A.Z histone variants on HBV replication
Basile Jay, Montpellier
Understanding the initial phase of HBV assembly: L-induced recruitment of empty and full capsids in late-endocytic-related domains
Carla Vanessa Sarabia Vega, Tours
Development of FXR agonists as antivirals against hepatitis viruses
Romain Barnault, Lyon
Capsid assembly modulators against HBV: old molecules with new mechanisms of action
Valerio Taverniti, Strasbourg
Base Editing to inhibit HBsAg expression
Anuj Kumar, Lyon
Chairs: Julie Lucifora, Vincent Thibault
HDV origin in Homo Sapiens
Frederic Le Gal, Bobigny
Intrahepatic decay of HDV during Bulevirtide therapy
Miroslava Subic Levrero, Lyon
Insight on HDV – host cell interactions for drug discovery
Eloi Verrier, Strasbourg
Mode of action of Nucleic Acid Polymers in HDV infection
Massimo Levrero, Lyon
Roundtable discussion
Chairs: Linda Wittkop, Fabien Zoulim
Results of clinical trials of novel cure strategies
Marc Bourlière, Marseille
CAM inhibitors as backbone treatments for functional cure
Raymond Schinazi, Atlanta
Targeting HBV RNAs with novel ASOs
Guofeng Cheng, AusperBio
Immunological correlates of functional cure
Georg Lauer, Boston
DC-targeting vaccines for HIV and emerging infectious diseases: perspectives for HBV
Yves Levy, Créteil
Roundtable discussion: HBV & HDV cure challenges
